FIP1L1-PDGFRA fusion gene in T-lymphoblastic lymphoma: A case report.
Salhah AliYasmine Al-QattanWalaa AwnyAbdulaziz HamadahKaren PintoSalem AlShemmariPublished in: Cancer reports (Hoboken, N.J.) (2022)
FIP1L1-PDGFRA-positive T-LBL and myeloproliferative disorders have excellent response to low-dose treatment with (TKI) imatinib. Most patients achieve rapid and complete hematologic and molecular remission within weeks.
Keyphrases
- low dose
- end stage renal disease
- ejection fraction
- newly diagnosed
- prognostic factors
- chronic myeloid leukemia
- high dose
- gene expression
- tyrosine kinase
- copy number
- patient reported outcomes
- rheumatoid arthritis
- dna methylation
- advanced non small cell lung cancer
- patient reported
- disease activity
- transcription factor
- ulcerative colitis
- gestational age
- replacement therapy